Hyponatremia is a common complication among cancer patients. Certain antineoplastic agents have been associated with syndrome of inappropriate secretion of anti-diuretic hormone-induced hyponatremia. The most common agents associated with secretion of anti-diuretic hormone are vinca alkaloids, platinum compounds, and alkylating agents. We report a case of secretion of anti-diuretic hormone associated with tyrosine kinase inhibitors.
BerghmansT. Hyponatremia related to medical anticancer treatment. Support Care Canc1996; 4: 341–350.
2.
LiapisKApostolidisJCharitakiE. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib. Ann Pharmacother2008; 42: 1882–1886.
3.
VerbalisJGGoldsmithSRGreenbergA. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. Am J Med2013; 126: S6–S36.
4.
DeiningerMWNO’BrienSGFordJM. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol2003; 21: 1637–1647.
5.
PillaiBPUnnikrishnanAGPavithranPV. Syndrome of inappropriate antidiuretic hormone secretion: Revisiting a classical endocrine disorder. Indian J Endocrinol Metab2011; 15: S208–S215.
6.
ChanTY. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management. Drugs Aging1997; 11: 27–44.
7.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
